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Abstract
Background and Aims
The prevalence and extent of liver damage in coronavirus disease 2019 (COVID-19) patients
remain poorly understood, primarily due to small-sized epidemiological studies with varying
definitions of “liver injury”. We conducted a meta-analysis to derive generalizable, well-
powered estimates of liver injury prevalence in COVID-19 patients. We also aimed to assess
whether liver injury prevalence is significantly greater than the baseline prevalence of chronic
liver disease (CLD). Our secondary aim was to study whether the degree of liver injury was
associated with the severity of COVID-19.
Materials and Methods
Electronic databases (PubMed and Scopus) were systematically searched in June 2020 for
studies reporting the prevalence of baseline CLD and current liver injury in hospitalized
COVID-19 patients. Liver injury was defined as an elevation in transaminases >3 times above
the upper limit of normal. For the secondary analysis, all studies reporting mean liver enzyme
levels in severe versus non-severe COVID-19 patients were included. A random-effects model
was used for meta-analysis. Proportions were subjected to arcsine transformation and pooled
to derive pooled proportions and corresponding 95% confidence intervals (CIs). Subgroup
differences were tested for using the chi-square test and associated p-value. Means and their
standard errors were pooled to derive weighted mean differences (WMDs) and corresponding
95% CIs.
Results
Electronic search yielded a total of 521 articles. After removal of duplicates and reviewing the
full-texts of potential studies, a total of 27 studies met the inclusion criteria. Among a cohort
of 8,817 patients, the prevalence of current liver injury was 15.7% (9.5%-23.0%), and this was
significantly higher than the proportion of patients with a history of CLD (4.9% [2.2%-8.6%]; p <
0.001). A total of 2,900 patients in our population had severe COVID-19, and 7,184 patients had
non-severe COVID-19. Serum ALT (WMD: 7.19 [4.90, 9.48]; p < 0.001; I2 = 69%), AST (WMD:
9.02 [6.89, 11.15]; p < 0.001; I2 = 73%) and bilirubin levels (WMD: 1.78 [0.86, 2.70]; p < 0.001; I 2 =
82%) were significantly higher in patients with severe COVID-19 when compared to patients
with non-severe disease. Albumin levels were significantly lower in patients with severe
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COVID-19 (WMD: -4.16 [-5.97, -2.35]; p < 0.001; I2 = 95%).
Conclusions
Patients with COVID-19 have a higher than expected prevalence of liver injury, and the extent
of the injury is associated with the severity of the disease. Further studies are required to assess
whether hepatic damage is caused by the virus, medications, or both.
Categories: Internal Medicine, Gastroenterology, Infectious Disease
Keywords: liver injury, liver abnormalities, coronavirus disease 2019, covid-19, liver injury biomarkers,
liver enzymes, hepatic injury, sars-cov-2
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), the virus responsible for
coronavirus disease 2019 (COVID-19), mainly affects the respiratory system causing symptoms
of fever, fatigue, cough, dyspnea, loss of appetite, muscle and joint pains [1]. However, the
incidence of vomiting, nausea, and diarrhea have also been reported, suggesting the
involvement of gastrointestinal and hepatobiliary systems [1,2]. SARS-Cov-2 enters cells
through the angiotensin-converting enzyme-2 (ACE2) protein. Apart from type II alveolar
epithelial cells of the lung, ACE2 protein is also expressed in the bile ducts cells [3]. This
suggests that SARS-Cov-2 could potentially infect bile duct cells and cause abnormal liver
function tests. According to one recent study, liver biopsy specimens of COVID-19 patients
demonstrated moderate microvascular steatosis and mild lobular and portal activity,
suggesting liver injury [4].
Although, in theory, liver injury in COVID-19 patients is possible, the actual prevalence and
extent of liver damage in these patients remain poorly understood. This is primarily because
most published COVID-19 studies are small-sized, often lack adjustment for baseline chronic
liver disease (CLD), and have inconsistent definitions of “liver injury”. In this meta-analysis, we
aim to provide well-powered and generalizable estimates of the prevalence of liver injury in
COVID-19 patients while making sure to keep the definition of “liver injury” consistent. We
also seek to assess whether the prevalence of liver injury in COVID-19 patients is significantly
different from the prevalence of baseline CLD in these patients. A secondary aim of this study
is to assess for any significant differences in serum biomarkers of liver injury (alanine
transaminase [ALT], aspartate transaminase [AST], total bilirubin, and albumin) in patients
with severe versus non-severe COVID-19.
Materials And Methods
This meta-analysis was conducted according to the Preferred Reporting Items for Systemic
Reviews and Meta-Analyses (PRISMA) guidelines [5].
Literature search
PubMed and Scopus were searched from the inception of databases till June 18, 2020, using the
following search string: (“novel coronavirus” OR “2019‐nCoV” OR “severe acute respiratory
syndrome coronavirus 2” OR “SARS-CoV-2” OR “coronavirus disease 2019” OR “COVID-19”)
AND (“Aspartate Aminotransferases” OR “SGOT” OR “Alanine Transaminase” OR “Alanine
aminotransferase” OR “SGPT” OR “Albumin” OR “Bilirubin” OR “Liver”) AND (“hepatic injury”
OR “liver injury” OR “liver damage” OR “liver abnormality”). Google Scholar was also searched
for grey literature. No language and time restrictions were set. The search strategy for both
databases is shown in Table 1.
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Electronic
database Search strategy
PubMed
(((((("novel coronavirus"[All Fields] OR "2019-nCoV"[All Fields]) OR "severe acute respiratory syndrome
coronavirus 2"[All Fields]) OR "SARS-CoV-2"[All Fields]) OR "coronavirus disease 2019"[All Fields]) OR
"COVID-19"[All Fields]) AND ((((((("Aspartate Aminotransferases"[All Fields] OR "SGOT"[All Fields]) OR
"Alanine Transaminase"[All Fields]) OR "Alanine aminotransferase"[All Fields]) OR "SGPT"[All Fields]) OR
"Albumin"[All Fields]) OR "Bilirubin"[All Fields]) OR "Liver"[All Fields])) AND ((("hepatic injury"[All Fields] OR
"liver injury"[All Fields]) OR "liver damage"[All Fields]) OR "liver abnormality"[All Fields])
Scopus
( TITLE-ABS-KEY ( "liver injury"  OR  " liver failure" OR "hepatic damage"  OR  "liver function abnormality" 
OR  "hepatic abnormality")  AND  TITLE-ABS-KEY ( "ALT"  OR  " alanine transaminase"  OR  "SGPT" )
AND  TITLE-ABS-KEY ( "AST"  OR  "  Aspartate transaminase"  OR  "SGOT" ) AND  TITLE-ABS-KEY (
"bilirubin"  OR  " total bilirubin") AND  TITLE-ABS-KEY ( "albumin"  OR  "serum albumin") AND  TITLE-ABS-
KEY ( "COVID-19"  OR  "SARS-CoV-2"  OR  "coronavirus disease" ))
TABLE 1: Search strategy for electronic databases
Study selection
All the articles were exported to EndNote Reference Library version X4 (Clarivate
Analytics, Philadelphia, PA) for screening and removal of duplicates. Studies were narrowed
down based on titles and abstracts, and final inclusion was performed after reviewing the full
texts of articles. Studies were selected independently by two reviewers, and a third reviewer
resolved any conflict regarding inclusion.
Inclusion criteria and definitions
We included all studies among COVID-19 patients that defined liver injury as an elevation in
transaminases >3 times above the upper limit of normal (ULN). To study whether the extent of
liver injury was associated with severity of COVID-19, all studies that reported serum ALT, AST,
total bilirubin, or albumin levels in severe versus non-severe COVID-19 patients were included.
Most of the studies assessed COVID-19 severity according to either the World Health
Organization interim guidance for COVID-19 or the guidelines for the diagnosis and
management of COVID-19 by the National Health Commission of China, thus ensuring
minimum heterogeneity in severity criteria. Case reports and studies that did not report the
definition of liver injury were excluded.
Data extraction
Data extraction was performed independently by two reviewers, and, in case of any conflict, the
opinion of a third reviewer was sought. Characteristics of included studies, patients’ baseline
information, liver injury biomarkers, and criteria for liver injury were extracted from the
studies on a predesigned form.
Statistical analysis
Open MetaAnalyst and Review Manager Version 5.4 were used for all statistical analyses.
Proportions from studies were subjected to arcsine transformation and pooled using a random-
effects model to derive the pooled proportions and corresponding 95% confidence intervals
(CIs). The chi-square test was used to assess for any significant differences between baseline
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CLD prevalence and prevalence of liver injury. Continuous variables were also pooled using a
random-effects model to derive the weighted mean difference (WMD) and 95% CIs. The Higgins
I2 statistic was used to evaluate heterogeneity and a value of 25%-50% was considered mild,
50%-75% as moderate, and >75% as severe heterogeneity. Publication bias was assessed
through visual inspection of the funnel plot. A p-value of less than 0.05 was considered
significant in all cases.
Results
The initial search yielded 513 potential articles, and eight records were identified through
references of relevant studies. After exclusions, 27 studies were used in our quantitative
analysis [1,2,4,6-29]. The PRISMA flowchart (Figure 1) summaries the results of our literature
search. The baseline characteristics and outcomes of included studies are given in Table 2.
Visual inspection of the funnel plot (based on serum ALT outcome) showed no publication bias
(Figure 2).
FIGURE 1: PRISMA flow chart summarizing the literature
search
PRISMA, Preferred Reporting Items for Systemic Reviews and Meta-Analyses
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Author
name Location
Study
design Total
Males
(%)
Age
(years)
Baseline
CLD (%) Outcomes
Bloom et
al. [2] USA Prospective 60
39
(65.0) 57 4 (7.0) Liver injury
Cai et al. [6] China Retrospective 298 145(48.7) 47.5 28 (9.4)
Liver injury; biomarkers: ALT,
AST, and T. bilirubin
Cai et al. [7] China Cross-sectional 417
298
(71.5) 47.32 21 (5.04)
Liver injury; biomarkers: ALT,
AST, and T. bilirubin
Chen et
al. [8] China Retrospective 21
17
(81.0) 56.5 NR
Biomarkers: ALT, AST, T.
bilirubin, and albumin
Chen et
al. [4] China Retrospective 274
171
(62.0) 59.5 NR
Biomarkers: ALT, AST, T.
bilirubin, and albumin
Deng et
al. [9] China Retrospective 225
124
(55.1) 54.5 NR Biomarkers: ALT and AST
Fu et al. [10] China Retrospective 355 190(53.5) >60=115 9 (2.5)
Biomarkers: ALT, AST, T.
bilirubin, and albumin
Gao et
al. [11] China Retrospective 43
26
(60.5) 44.08 NR Biomarkers: ALT and AST
Huang C et
al. [1] China Retrospective 41
30
(73.0) 49 1 (3.6) Biomarkers: ALT and AST
Jin et al. [12] China Retrospective 651 331(50.8) 45.61 25 (3.8)
Biomarkers: ALT, AST, T.
bilirubin, and albumin
Lei et al. [13] China Retrospective 5,771 2,724(47.2) 56 81 (1.4) Liver injury
Liu et al. [14] China Retrospective 78 39(50.0) 51.5 NR
Biomarkers: ALT, AST, and
albumin
Mo et
al. [15] China Retrospective 155
86
(55.5) 53.5 7 (4.5)
Biomarkers: ALT, AST, and
albumin
Pan et
al. [16] China Retrospective 204
107
(52.5) 52.9 2 (0.01)
Biomarkers: ALT, AST, T.
bilirubin, and albumin
Phipps et
al. [17] USA Retrospective 2,273
1,297
(57.1) 65 114 (5.0) Liver injury
Qian et
al. [18] China Retrospective 91
37
(40.7) 57.5 NR
Biomarkers: ALT, AST, and
albumin
Qu et al. [19] China Retrospective 30 16(53.3) 54.7
Excluded
(0) Biomarkers: ALT and AST
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Ruan et
al. [20]
China Retrospective 150 102
(68)
58.5 4 (2.7) Biomarkers: T. bilirubin and
albumin
Wan et
al. [21] China Retrospective 135
72
(53.3) 50 2 (1.5)
Biomarkers: ALT, AST, T.
bilirubin, and albumin
Wang et
al. [22] China Retrospective 138
75
(54.3) 58.5 4 (2.9)
Biomarkers: ALT, AST, and T.
bilirubin
Wang et
al. [23] China Retrospective 69 32 (46) 53.7 1 (1.4) Biomarkers: ALT and AST
Wu et
al. [24] China Retrospective 201
128
(63.7) 53.25 7 (3.5)
Biomarkers: ALT, AST, T.
bilirubin, and albumin
Xie et
al. [25] China Retrospective 79
44
(55.7) 60
Excluded
(0)
Biomarkers: ALT, AST, and T.
bilirubin
Yang et
al. [26] China Retrospective 52
35
(67.0) 58.25 16 (30.8) Biomarkers: T. bilirubin
Zhang et
al. [27] China Retrospective 645
328
(50.9) 40.77 25 (3.9)
Biomarkers: ALT, AST, T.
bilirubin, and albumin
Zhou et
al. [28] China Retrospective 34
17
(50.0) 65 NR Biomarkers: ALT and AST
Zhou et
al. [29] China Retrospective 191
119
(62.0) 60.5 NR Biomarkers: ALT and albumin
TABLE 2: Baseline characteristics and demographics of the included studies
CLD, chronic liver disease; ALT, alanine transaminase; AST, aspartate transaminase; T. bilirubin, total bilirubin; NR, not reported
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FIGURE 2: Funnel plot for publication bias
The funnel plot is based on serum ALT levels.
SE, standard error; MD, mean difference; ALT, alanine transaminase
Liver injury
Liver injury was defined as an elevation in transaminases >3 times above the ULN. Five studies,
including 8,817 COVID-19 positive patients, met the pre-defined inclusion criteria for liver
injury [2,6,7,13,17]. The pooled proportion of patients with a history of CLD was 4.9% (2.2%-
8.6%]) The prevalence of liver injury was 15.7% (9.5%-23.0%), as shown in Figure 3, and this
was significantly higher than the baseline CLD prevalence (p < 0.001).
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FIGURE 3: Pooled prevalence of (A) patients with a history of
chronic liver disease and (B) patients with liver injury
CI, confidence interval; Ev/Trt, events/total; I2, heterogeneity
Biomarkers of liver injury in severe versus non-severe COVID-
19 patients
Levels of liver biomarkers were reported by 25 studies comprising 10,084 patients (2,900 severe
COVID-19 and 7,184 non-severe COVID-19 patients) [1,4,6-16,18-29]. Our analysis shows that
serum ALT (WMD: 7.19 [4.90, 9.48]; p < 0.001; I2 = 69%), AST (WMD: 9.02 [6.89, 11.15]; p <
0.001; I2 = 73%), and total bilirubin levels (WMD: 1.78 [0.86, 2.70]; p < 0.001; I 2 = 82%) were
significantly higher in patients with severe COVID-19 when compared to patients with non-
severe disease. Albumin levels were significantly lower in patients with severe COVID-19
(WMD: -4.16 [-5.97, -2.35]; p < 0.001; I2 = 95%). The individual forest plots for ALT, AST, total
bilirubin, and albumin are shown in Figures 4-7, respectively.
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FIGURE 4: Forest plot showing the association between serum
ALT levels and severity of disease in COVID-19 patients
SD, standard deviation; IV, inverse variance; CI, confidence interval; ALT, alanine transaminase;
COVID-19, coronavirus disease 2019
FIGURE 5: Forest plot showing the association between serum
AST levels and severity of disease in COVID-19 patients
SD, standard deviation; IV, inverse variance; CI, confidence interval; AST, aspartate transaminase;
COVID-19, coronavirus disease 2019
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FIGURE 6: Forest plot showing the association between serum
total bilirubin levels and severity of disease in COVID-19
patients
SD, standard deviation; IV, inverse variance; CI, confidence interval; COVID-19, coronavirus
disease 2019
FIGURE 7: Forest plot showing the association between serum
albumin levels and severity of disease in COVID-19 patients
SD, standard deviation; IV, inverse variance; CI, confidence interval; COVID-19, coronavirus
disease 2019
The serum levels of all biomarkers for severe and non-severe COVID-19 patients in each study
are given in Table 3. The criterion used to diagnose COVID-19 in each study is given in the
Appendices section.
Author
Name
No. of COVID-19 patients Mean serum ALT levels Mean serum AST levels
Mean serum total bilirubin
levels
Mean serum albumin levels
Severe
COVID-19
Non-severe
COVID-19
Severe
COVID-19
Non-severe
COVID-19
Severe
COVID-19
Non-severe
COVID-19
Severe
COVID-19
Non-severe
COVID-19
Severe
COVID-19
Non-severe
COVID-19
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Cai et al.
[6]
58 240 26.85±16.32 20±12.11 36±15.9 26±10.83 11.25±7.76 10.9±1.18 - -
Cai et al.
[7]
85 233 67±42.0 41±33.47 58±41.08 34±14.41 22±7.88 19±10.38 - -
Chen et
al. [8]
11 10 42±12.96 16±6.29 47±34.44 24±3.70 8.80±1.92 7.80±2.29 29.60±3.25 37.20±2.22
Chen et
al. [4]
113 161 28.00±21.48 20.00±12.74 45.00±26.66 25.00±9.85 12.60±4.4 8.40±4.00 30.10±3.77 36.30±4.29
Deng et
al. [9]
109 116 22.00±14.07 18.70±13.2 34.00±14.81 22.00±10.44 - - - -
Fu et
al. [10]
88 211 23.0±20.39 22.0±15.99 29.0±24.5 26.0±11.94 10.9±6.47 10.4±5.75 37.3±5.0 40.5±5.75
Gao et
al. [11]
15 28 27.00±14.81 24.50±16.29 27.80±11.42 33.21±18.24 - - - -
Huang et
al. [1]
13 28 49.00±63.7 27.00±15.18 44.00±29.62 34.00±12.22 14.00±15.55 10.80±2.14 - -
Jin et
al. [12]
74 577 25.00±16.82 21.50±13.18 29.35±13.14 24.40±9.62 10.00±4.92 9.60±4.51 40.13±4.92 41.50±3.8
Lei et
al. [13]
1186 4585 26.0±22.47 23.0±18.31 31.0±20.01 22.0±11.05 10.6±5.62 10.3±4.84 - -
Liu et
al. [14]
11 67 17.40±22.22 18.50±11.25 21.60±24.88 20.00±12.59 - - 36.62±6.6 41.27±4.55
Mo et
al. [15]
85 70 28.00±18.51 20.00±13.33 37.00±29.62 32.00±11.11 - - 36.00±5.92 39.00±4.44
Pan et
al. [16]
103 101 42.24±43.83 29.53±23.58 35.12±26.58 27.48±23.98 13.83±12.03 13.46±8.11 36.16±6.49 35.84±5.63
Qian et
al. [18]
9 82 19.90±8.88 18.00±11.85 27.00±2.4 21.00±8.88 - - 38.55±2.16 40.20±3.25
Qu et
al. [19]
3 27 36.00±19.52 33.59±24.54 45.33±12.9 43.56±21.03 - - - -
Ruan et
al. [20]
68 82 - - - - 18.10±10.7 12.80±6.8 28.80±3.8 32.70±3.8
Wan et
al. [21]
40 95 26.60±13.92 21.70±16.37 33.60±13.70 22.40±10.07 9.80±5.77 8.60±6.22 36.00±4.0 49.90±4.59
Wang et
al. [22]
36 102 35.00±28.14 23.00±15.55 52.00±29.62 29.00±12.59 11.50±6.66 9.30±3.40 - -
Wang et
al. [23]
14 55 31.50±21.48 24.00±17.77 40.50±28.14 26.00±13.33 - - - -
Wu et
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al. [24]
84 117 35.00±22.96 27.00±17.40 38.00±16.66 30.00±10.74 12.90±5.59 10.50±3.74 30.40±4.59 33.70±3.96
Xie et
al. [25]
28 51 36.5±41.31 30.0±17.6 35±22.95 28±20.34 12.7±5.6 13.9±7.64 - -
Yang et
al. [26]
32 20 - - - - 19.50±11.6 13.10±4.3 - -
Zhang et
al. [27]
573 72 29.37±25.71 25.53±19.96 30.08±20.37 25.67±15.52 11.26±8.04 9.11±4.86 41.02±4.47 42.53±4.7
Zhou et
al. [28]
8 26 49.00±34.07 34.00±29.62 44.00±16.29 32.00±14.81 - - - -
Zhou et
al. [29]
54 137 40.00±20.0 27.00±18.51 - - - - 29.10±3.55 33.60±4.29
TABLE 3: Serum levels of ALT, AST, total bilirubin, and albumin among severe and
non-severe COVID-19 patients in the included studies
COVID-19, coronavirus disease 2019; ALT, alanine transaminase; AST, aspartate transaminase
Discussion
Our meta-analysis has three salient findings. Firstly, almost 16% of the COVID-19 positive
patients had a substantial elevation in enzymes (>3 times the ULN). Secondly, the prevalence of
current liver injury in hospitalized COVID-19 patients was significantly higher than the
prevalence of patients with known pre-COVID CLD. Thirdly, the extent of liver damage was
associated with the severity of COVID-19.
Although our study demonstrates a clear association between COVID-19 and liver injury,
mechanisms for liver injury remain unclear. Direct injury by SARS-CoV-2 has been proposed as
a likely mechanism [3]. The expression of ACE2 protein (entry receptor for SARS-CoV-2) on bile
duct cells supports the possibility of virus-mediated liver damage [3]. However, there is a lower
frequency of receptors found in liver cells than bile duct cells, and trends show an elevation in
aminotransferases rather than alkaline phosphate and gamma-glutamyl transferase [3,6,7,17].
Thus, alternate mechanisms must be considered as well.
Apart from direct viral-mediated injury, drug-induced liver injury must also be given
consideration. Acetaminophen, a drug commonly used by COVID-19 patients, is known to
cause hepatic injury at doses >7.5 to 10 g in adults [30]. In addition, the simultaneous use of
multiple antiviral therapies and antibiotics in these patients can be hepatotoxic [17,21-23].
Aggressive treatment in patients with more severe disease may explain the association of liver
injury with disease severity seen in our study.
Systemic effects of COVID-19 could be another possible explanation for the liver injury. It is
proven that SARS-Cov-2 infects the lung causing hypoxia and, in severe cases, acute
respiratory distress syndrome, sepsis, and multi-organ failure [1,4,9,17]. It can be imagined that
sepsis in COVID-19 leads to hypoxic injury and ischemia of the liver, causing elevated liver
biochemistries, which further explains why serum ALT, AST, and total bilirubin levels are higher
in severe/ICU COVID-19 patients than non-severe patients, as demonstrated in our
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study [6,7,17].
To the best of our knowledge, this is the first meta-analysis to report the prevalence of liver
injury in COVID-19 patients while keeping the definition of liver injury standard and
accounting for baseline CLD history. Thus, these results should be generalizable across cohorts
of hospitalized COVID-19 patients. Our results should stimulate further research interest in the
area in order to uncover mechanisms contributing to liver injury.
Limitations
This study has certain important limitations. Firstly, the quality of data-collection methods and
data reported in individual studies cannot be ascertained. Secondly, patients can sometimes be
unaware of underlying CLD (e.g., in non-alcoholic fatty liver disease), and these patients may
be misclassified as having no CLD. This could have led to an underestimation of baseline CLD
prevalence. Third, as shown, estimates from our study had significantly high heterogeneity.
This is likely due to the inclusion of primarily small studies with varied prevalence. Lastly, all
included studies were of observational nature, and there is a need for randomized trials on this
aspect of COVID-19. Although meta-analysis can increase the power and provide better
estimates, the results are intended to offer early insight and should not be considered a
replacement for large-scale observational studies that are being awaited.
Conclusions
This systematic review and meta-analysis shows that COVID-19 is associated with an increased
incidence of liver injury. Furthermore, the extent of derangement in serum liver function
markers is associated with the severity of COVID-19. Future studies should adopt a pre-defined
criterion for reporting liver injury and exclude those patients from the analyses that had any
form of baseline derangement in liver enzymes and biomarkers at hospital admission. A
standard protocol should be formed for COVID-19 patients to identify them as "with liver
injury" or "without liver injury", as this will lead to uniform reporting and low bias in studies.
Appendices
Author
name Diagnostic criteria
 
 
Cai et al.
[6] WHO interim guidance for COVID-19  
Cai et al.
[7]
Handbook of Prevention and Treatment of the Pneumonia Caused by the 2019-nCoV by National Health
Commission of China  
Chen et
al. [8]
6th edition guidelines for diagnosis and management of COVID-19 by the National Health Commission of
China  
Chen et
al. [4]
6th edition guidelines for diagnosis and management of COVID-19 by the National Health Commission of
China  
Deng et
al. [9]
6th edition guidelines for diagnosis and management of COVID-19 by the National Health Commission of
China  
Fu et
al. [10]
Diagnosed on basis of typical clinical manifestations accompanied with characteristic chest radiology
changes  
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Gao et
al. [11]
WHO interim guidance for COVID-19  
Huang et
al. [1]
Diagnosis of pneumonia was based on clinical characteristics, chest imaging, and excluding common
pathogens that cause pneumonia  
Jin et
al. [12]
6th edition guidelines for diagnosis and management of COVID-19 by the National Health Commission of
China  
Lei et
al. [13] WHO interim guidance for COVID-19  
Liu et
al. [14]
4th edition guidelines for diagnosis and management of COVID-19 by the National Health Commission of
China  
Mo et
al. [15] Diagnosis of pneumonia was based on clinical characteristics and chest imaging  
Pan et
al. [16] WHO interim guidance for COVID-19  
Qian et
al. [18]
4th and 5th edition guidelines for diagnosis and management of COVID-19 by the National Health
Commission of China  
Qu et
al. [19]
6th edition guidelines for diagnosis and management of COVID-19 by the National Health Commission of
China  
Ruan et
al. [20] Pneumonia was diagnosed on clinical characteristics and chest imaging  
Wan et
al. [21] WHO interim guidance for COVID-19  
Wang et
al. [22] WHO interim guidance for COVID-19  
Wang et
al. [23]
6th edition guidelines for diagnosis and management of COVID-19 by the National Health Commission of
China  
Wu et
al. [24] WHO interim guidance for COVID-19  
Xie et
al. [25] WHO interim guidance with laboratory-identified COVID-19  
Yang et
al. [26] WHO interim guidance for COVID-19  
Zhang et
al. [27]
WHO interim guidance for COVID-19 and 6th edition guidelines for diagnosis and management of COVID-
19 by the National Health Commission of China  
Zhou et
al. [28]
4th edition guidelines for diagnosis and management of COVID-19 by the National Health Commission of
China  
Zhou et
al. [29]
WHO interim guidance for COVID-19 and 6th edition guidelines for diagnosis and management of COVID-
19 by the National Health Commission of China  
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TABLE 4: Diagnostic criteria used for the assessment of severity of COVID-19 among
patients in the included studies
WHO, World Health Organization; COVID-19, coronavirus disease 2019; 2019-nCoV, 2019 novel coronavirus
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